Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06218706

LIFU for Treatment for Refractory Opioid Use Disorder

This is a randomized, double-blind, sham-controlled, partial crossover study investigating LIFU targeting the NAc and VC for participants with severe, treatment refractory OUD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

WVU Rockefeller Neuroscience Institute

Morgantown, West Virginia, 26505, United States

Location status: Recruiting

Location contact

James Mahoney, PhD

CONTACT

About this study

The overall objective of this study is to assess the safety, tolerability, and feasibility of using Low Intensity Focused Ultrasound (LIFU) to treat opioid use disorder (OUD) as well as investigate the potential impact on substance use and risk factors associated with drug use recurrence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 22 - 60 years at time of enrollment.
  • Fulfill current DSM-5 (American Psychiatric Association diagnostic and statistical manual of mental disorders, 5th ed, 2013) diagnostic criteria for severe OUD with at least a 2-year history.
  • Women of reproductive potential must have negative pregnancy test and agree to use acceptable forms of contraception.

Exclusion criteria

  • Unable to undergo MR-imaging because of non-MR compatible implants (e.g., pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have), or if candidates are uncomfortable in small spaces (have claustrophobia) or cannot lie comfortably on their back for 2-3 hours.
  • History of any clinically significant neurological disorder (e.g., brain surgery, tumors, uncontrolled epilepsy, or any others deemed clinically significant by the investigator).
  • History of stroke or brain lesion in the targeted brain region (the NAc, ventral striatum, or VC).
  • Implanted neurostimulators (e.g., vagus nerve stimulator, spinal cord stimulator, DBS).
  • Documentation of clinically significant MRI abnormality indicative of a neurological condition or abnormality that may jeopardize the participant's safety, study conduct, or confound the participant's diagnostic assessments.
  • More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.
  • Subject with chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area.
  • Subject with impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2
  • Hepatic function laboratory values which are > 1.5 times the upper limit of normal unless deemed not clinically significant by a study investigator.
  • Past or present diagnosis of schizophrenia or psychotic disorder.
  • Subject unwilling to attempt abstinence from illicit substance use during the course of the study.
  • Unable to speak, read and understand English.
  • Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator.

Treatment and study plan

Low Intensity Focussed Ultrasound

Device

The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    Time frame: Post-ExAblate Procedure through 90 day Follow-Up

    Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurrence.

  2. Changes in Opioid Use

    Time frame: Post-ExAblate Procedure through 90 day Follow-Up

    Changes in opioid use will be measured using quantitative urine toxicology via liquid chromatography/mass spectrometry (LC/MS).

Study contacts

Contact information is provided by the study sponsor or research team.

James Mahoney

CONTACT

[email protected]

3042935323

Jennifer Marton

CONTACT

[email protected]

3042935886

Sponsors and collaborators

Lead sponsor

Ali Rezai

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

A Randomized, Sham-Controlled Trial Investigating Low Intensity Focused Ultrasound as a Novel Treatment for Refractory Opioid Use Disorder

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Jan 23, 2024
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.